Scholarlink

Background <p>Left atrial macroreentrant tachycardias (LAMRTs) are increasing, particularly following atrial fibrillation ablation. Conventional ablation strategies based on activation mapping are limited by the presence of multiple inducible circuits and high recurrence rates. The potential benefit of a substrate-guided approach targeting reproducible anatomical reentry pathways remains unknown. We hypothesize that a substrate-guided approach, targeting reproducible anatomical pathways sustaining reentry rather than only inducible tachycardias, will improve rhythm control and clinical outcomes compared with conventional ablation strategies.</p> Objective <p>The goal of this trial is to determine whether substrate-guided catheter ablation is superior to activation-guided ablation in reducing atrial arrhythmia recurrence in patients with LAMRT.</p> Methods <p>The SLICE-LAMRT trial is an investigator-initiated, prospective, multicenter, randomized (1:1) study conducted at 12 centers in Spain. Patients and clinical event adjudicators are blinded to treatment allocation. Patients with LAMRT and significant left atrial low-voltage substrate are randomized to either a conventional activation-guided ablation strategy, based on high-density mapping and entrainment pacing of clinical and inducible tachycardias, or a substrate-guided approach consisting of a predefined left atrial ablation line set. This study has been registered at ClinicalTrials.gov (NCT05842499). The primary endpoint is atrial tachyarrhythmia recurrence and time to first recurrence after a 3-month blanking period. Secondary endpoints include procedural performance, acute efficacy, major clinical outcomes (including hospitalizations and mortality), and echocardiographic parameters. Safety endpoints include procedure-related adverse events such as death, stroke, cardiac tamponade, vascular complications, and other major complications.</p> Conclusion <p>The SLICE-LAMRT trial will provide the first randomized evidence comparing substrate-guided and activation-guided ablation strategies in LAMRT. By addressing a major unmet clinical need, this study may inform and refine ablation strategies for atypical atrial flutter and support a shift toward substrate-based approaches in complex atrial arrhythmias.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Substrate ablation as concomitant treatment for left atrial macroreentrant tachycardia (SLICE-LAMRT): rationale and study design

  • 期刊论文

  • 发表日期：

    2026年5月28日

查看全文
  • Daniel Rodríguez-Muñoz,
  • Lucía Cobarro,
  • Isabel López-Alacid,
  • Martín Negreira-Caamaño,
  • Lorena Gómez-Burgueño,
  • Javier Ramos-Jiménez,
  • Ez Alddin Rajjoub Al-Mahdi,
  • Álvaro Marco del Castillo,
  • Luis Borrego-Bernabé,
  • Juan Delgado,
  • Rafael Salguero-Bodes,
  • Fernando Arribas-Ynsaurriaga

摘要

Background

Left atrial macroreentrant tachycardias (LAMRTs) are increasing, particularly following atrial fibrillation ablation. Conventional ablation strategies based on activation mapping are limited by the presence of multiple inducible circuits and high recurrence rates. The potential benefit of a substrate-guided approach targeting reproducible anatomical reentry pathways remains unknown. We hypothesize that a substrate-guided approach, targeting reproducible anatomical pathways sustaining reentry rather than only inducible tachycardias, will improve rhythm control and clinical outcomes compared with conventional ablation strategies.

Objective

The goal of this trial is to determine whether substrate-guided catheter ablation is superior to activation-guided ablation in reducing atrial arrhythmia recurrence in patients with LAMRT.

Methods

The SLICE-LAMRT trial is an investigator-initiated, prospective, multicenter, randomized (1:1) study conducted at 12 centers in Spain. Patients and clinical event adjudicators are blinded to treatment allocation. Patients with LAMRT and significant left atrial low-voltage substrate are randomized to either a conventional activation-guided ablation strategy, based on high-density mapping and entrainment pacing of clinical and inducible tachycardias, or a substrate-guided approach consisting of a predefined left atrial ablation line set. This study has been registered at ClinicalTrials.gov (NCT05842499). The primary endpoint is atrial tachyarrhythmia recurrence and time to first recurrence after a 3-month blanking period. Secondary endpoints include procedural performance, acute efficacy, major clinical outcomes (including hospitalizations and mortality), and echocardiographic parameters. Safety endpoints include procedure-related adverse events such as death, stroke, cardiac tamponade, vascular complications, and other major complications.

Conclusion

The SLICE-LAMRT trial will provide the first randomized evidence comparing substrate-guided and activation-guided ablation strategies in LAMRT. By addressing a major unmet clinical need, this study may inform and refine ablation strategies for atypical atrial flutter and support a shift toward substrate-based approaches in complex atrial arrhythmias.

Graphical abstract